[1] Duyckaerts C, Delatour B, Potier MC.Classification and basic pathology of Alzheimer disease[J]. Acta Neuropathol, 2009, 118(1): 5-36.
[2] Penke B, Szűcs M, Bogár F.Oligomerization and Conformational Change Turn Monomeric beta-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis[J]. Molecules, 2020, 25(7): 1659.
[3] 2020 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2020, 19(4): 1598-1695.
[4] Jack CR Jr, Albert MS, Knopman DS, et al.Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7(3): 257-262.
[5] Sabbagh MN.Alzheimer's Disease Drug Development Pipeline 2020[J]. J Prev Alzheimers Dis, 2020, 7(2): 66-67.
[6] McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7(3): 263-269.
[7] Yaari R, Fleisher AS, Tariot PN. Updates to diagnostic guidelines for Alzheimer's disease[J]. Prim Care Companion CNS Disord, 2011, 13(5): PCC.11f01262.
[8] Yu JT, Tan L, Hardy J.Apolipoprotein E in Alzheimer's disease: an update[J]. Annu Rev Neurosci, 2014, 37: 79-100.
[9] Bowen DM, Smith CB, White P, et al.Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies[J]. Brain, 1976, 99(3): 459-496.
[10] Liu J, Chang L, Song Y, et al.The Role of NMDA Receptors in Alzheimer's Disease[J]. Front Neurosci, 2019, 13: 43
[11] Hampel H, Mesulam MM, Cuello AC, et al.The cholinergic system in the pathophysiology and treatment of Alzheimer's disease[J]. Brain, 2018, 141(7): 1917-1933.
[12] Agrawal M, Saraf S, Saraf S, et al.Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs[J]. J Control Release, 2018, 281: 139-177.
[13] Haig GM, Bain EE, Robieson WZ, et al.A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective alpha7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia[J]. Am J Psychiatry, 2016, 173(8): 827-835.
[14] Long JM, Holtzman DM.Alzheimer Disease: An Update on Pathobiology and Treatment Strategies[J]. Cell, 2019, 179(2): 312-339.
[15] Schenk D, Barbour R, Dunn W, et al.Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature, 1999, 400(6740): 173-177.
[16] Orgogozo JM, Gilman S, Dartigues JF, et al.Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization[J]. Neurology, 2003, 61(1): 46-54.
[17] Schneider L.A resurrection of aducanumab for Alzheimer's disease[J]. Lancet Neurology, 2020, 19(2): 111-112.
[18] Loureiro JC, Pais MV, Stella F, et al.Passive antiamyloid immunotherapy for Alzheimer's disease[J]. Curr Opin Psychiatry, 2020, 33(3): 284-291.
[19] Beel AJ, Sanders CR.Substrate specificity of gamma-secretase and other intramembrane proteases[J]. Cell Mol Life Sci, 2008, 65(9): 1311-1334.
[20] Alberdi E, Sánchez-Gómez MV, Cavaliere F, et al.Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors[J]. Cell Calcium, 2010, 47(3): 264-272.
[21] Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation,Human Disease: A Summary of Progress Over the Last Decade[J]. Annu Rev Biochem, 2017, 86: 27-68.
[22] Schneider LS, Mangialasche F, Andreasen N, et al.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014[J]. J Intern Med, 2014, 275(3): 251-283.
[23] Choi ML, Gandhi S.Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases[J]. FEBS J, 2018, 285(19): 3631-3644.
[24] Selkoe DJ, Hardy J.The amyloid hypothesis of Alzheimer's disease at 25 years[J]. EMBO Mol Med, 2016, 8(6): 595-608.
[25] Chen XQ, Mobley WC.Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Abeta and Tau Species[J]. Front Neurosci, 2019, 13: 659.
[26] Cline EN, Bicca MA, Viola KL, et al.The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade[J]. J Alzheimers Dis, 2018, 64(s1): S567-S610.
[27] García-Escudero V, Gargini R, Martín-Maestro P, et al.Tau mRNA 3'UTR-to-CDS ratio is increased in Alzheimer disease[J]. Neurosci Lett, 2017, 655: 101-108.
[28] Berriman J, Serpell LC, Oberg KA, et al.Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure[J]. Proc Natl Acad Sci U S A, 2003, 100(15): 9034-9038.
[29] Hoover BR, Reed MN, Su J, et al.Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration[J]. Neuron, 2010, 68(6): 1067-1081.
[30] Zhou L, McInnes J, Wierda K, et al. Tau association with synaptic vesicles causes presynaptic dysfunction[J]. Nat Commun, 2017, 8: 15295.
[31] Yoo JH, Valdovinos MG, Williams DC.Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature[J]. J Autism Dev Disord, 2007, 37(10): 1883-1901.
[32] Wang H, Zhang HY.Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease[J]. Acs Chemical Neuroscience, 2019, 10(2): 852-862.
[33] Mesulam MM.Cholinergic Circuitry of the Human Nucleus Basalis and Its Fate in Alzheimer's Disease[J]. J Comp Neurol, 2013, 521(18): 4124-4144.
[34] Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits? [J]. Mol Aspects Med, 2015, 43-44: 25-37.
[35] Martorana A, Koch G."Is dopamine involved in Alzheimer's disease?"[J]. Front Aging Neurosci, 2014, 6: 252.
[36] Luebke JI, Weaver CM, Rocher AB, et al.Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models[J]. Brain Struct Funct, 2010, 214(2-3): 181-199.
[37] Whitehouse PJ, Price DL, Clark AW, et al.Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis[J]. Annals of neurology, 1981, 10(2): 122-126.
[38] Drachman DA, Leavitt J.Human memory and the cholinergic system. A relationship to aging?[J]. Arch Neurol, 1974, 30(2): 113-121.
[39] Summers WK, Majovski LV, Marsh GM, et al.Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type[J]. N Engl J Med, 1986, 315(20): 1241-1245.
[40] Calsolaro V, Edison P.Neuroinflammation in Alzheimer's disease: Current evidence and future directions[J]. Alzheimers Dement, 2016, 12(6): 719-732.
[41] McGeer PL, Rogers J, McGeer EG. Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years[J]. J Alzheimers Dis, 2016, 54(3): 853-857.
[42] Mrak RE, Griffinbc WS.The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease[J]. Neurobiol Aging, 2001, 22(6): 915-922.
[43] Hong S, Beja-Glasser VF, Nfonoyim BM, et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models[J]. Science, 2016, 352(6286): 712-716.
[44] Somers C, Goossens J, Engelborghs S, et al.Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel[J]. Biomark Med, 2017, 11(2): 169-178.
[45] Shevchenko A, Simons K.Lipidomics: coming to grips with lipid diversity[J]. Nat Rev Mol Cell Biol, 2010, 11(8): 593-598.
[46] Wong MW, Braidy N, Poljak A, et al.Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers[J]. Alzheimers Dement, 2017, 13(7): 810-827.
[47] Brugger B.Lipidomics: analysis of the lipid composition of cells and subcellular organelles by electrospray ionization mass spectrometry[J]. Annu Rev Biochem, 2014, 83: 79-98.
[48] Fahy E, Subramaniam S, Murphy RC, et al.Update of the LIPID MAPS comprehensive classification system for lipids[J]. J Lipid Res, 2009, 50(Suppl): S9-14.
[49] Mesa-Herrera F, Taoro-González L, Valdés-Baizabal C, et al.Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers[J]. Int J Mol Sci, 2019, 20(15): 3810.
[50] Chew H, Solomon VA, Fonteh AN.Involvement of Lipids in Alzheimer's Disease Pathology and Potential Therapies[J]. Front Physiol, 2020, 11: 598.
[51] Cunnane SC, Schneider JA, Tangney C, et al.Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease[J]. J Alzheimers Dis, 2012, 29(3): 691-697.
[52] Fonteh AN, Cipolla M, Chiang AJ, et al.Polyunsaturated Fatty Acid Composition of Cerebrospinal Fluid Fractions Shows Their Contribution to Cognitive Resilience of a Pre-symptomatic Alzheimer's Disease Cohort[J]. Front Physiol, 2020, 11: 83.
[53] Han X, M Holtzman D, McKeel DW Jr, et al. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis[J]. J Neurochem, 2002, 82(4): 809-818.
[54] Jazvinšćak Jembrek M, Hof PR, Šimić G.Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and A beta Accumulation[J]. Oxid Med Cell Longev, 2015, 2015: 346783.
[55] Kosicek M, Hecimovic S.Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers[J]. Int J Mol Sci, 2013, 14(1): 1310-1322.
[56] Sanchez-Mejia RO, Newman JW, Toh S, et al.Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease[J]. Nat Neurosci, 2008, 11(11): 1311-1318.
[57] El Gaamouch F, Jing P, Xia J, et al.Alzheimer's Disease Risk Genes and Lipid Regulators[J]. J Alzheimers Dis, 2016, 53(1): 15-29.
[58] Bennett SA, Valenzuela N, Xu H, et al.Using neurolipidomics to identify phospholipid mediators of synaptic (dys) function in Alzheimer's Disease[J]. Front Physiol, 2013, 4: 168.
[59] Yin F.Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise[J]. FEBS J, 2023, 290(6): 1420-1453.
[60] Karch CM, Goate AM.Alzheimer's disease risk genes and mechanisms of disease pathogenesis[J]. Biol Psychiatry, 2015, 77(1): 43-51.
[61] Hao S, Wang R, Zhang Y, et al.Prediction of Alzheimer's Disease-Associated Genes by Integration of GWAS Summary Data and Expression Data[J]. Front Genet, 2018, 9: 653.
[62] Wernette-Hammond ME, Lauer SJ, Corsini A, et al.Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194[J]. J Biol Chem, 1989, 264(15): 9094-9101.
[63] Chen Y, Strickland MR, Soranno A, et al.Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis[J]. Neuron, 2021, 109(2): 205-221.
[64] Houlden H, Crook R, Backhovens H, et al.ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families[J]. Am J Med Genet, 1998, 81(1): 117-121.
[65] Bandaru VV, Troncoso J, Wheeler D, et al.ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain[J]. Neurobiol Aging, 2009, 30(4): 591-599.
[66] Chartier-Harlin MC, Parfitt M, Legrain S, et al.Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region[J]. Hum Mol Genet, 1994, 3(4): 569-574.
[67] Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, et al.APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms[J]. Mol Psychiatry, 2014, 19(11): 1243-1250.
[68] Corder EH, Saunders AM, Risch NJ, et al.Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease[J]. Nat Genet, 1994, 7(2): 180-184.
[69] Liu CC, Liu CC, Kanekiyo T, et al.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy[J]. Nat Rev Neurol, 2013, 9(2): 106-118.
[70] Neu SC, Pa J, Kukull W, et al.Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis[J]. JAMA Neurol, 2017, 74(10): 1178-1189.
[71] Farrer LA, Cupples LA, Haines JL, et al.Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium[J]. Jama, 1997, 278(16): 1349-1356.
[72] Genin E, Hannequin D, Wallon D, et al.APOE and Alzheimer disease: a major gene with semi-dominant inheritance[J]. Mol Psychiatry, 2011, 16(9): 903-907.
[73] Giau VV, Bagyinszky E, An SS, et al.Role of apolipoprotein E in neurodegenerative diseases[J]. Neuropsychiatr Dis Treat, 2015, 11: 1723-1737.
[74] Paloneva J, Manninen T, Christman G, et al.Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype[J]. Am J Hum Genet, 2002, 71(3): 656-662.
[75] Guerreiro RJ, Lohmann E, Brás JM, et al.Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement[J]. JAMA Neurol, 2013, 70(1): 78-84.
[76] Yeh FL, Wang Y, Tom I, et al.TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia[J]. Neuron, 2016, 91(2): 328-340.
[77] Wang Y, Cella M, Mallinson K, et al.TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model[J]. Cell, 2015, 160(6): 1061-1071.
[78] Kober DL, Brett TJ.TREM2-Ligand Interactions in Health and Disease[J]. J Mol Biol, 2017, 429(11): 1607-1629.
[79] Cruchaga C, Kauwe JS, Harari O, et al.GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease[J]. Neuron, 2013, 78(2): 256-268.
[80] Guerreiro R, Wojtas A, Bras J, et al.TREM2 variants in Alzheimer's disease[J]. N Engl J Med, 2013, 368(2): 117-177.
[81] Kim WS, Weickert CS, Garner B.Role of ATP-binding cassette transporters in brain lipid transport and neurological disease[J]. J Neurochem, 2008, 104(5): 1145-1166.
[82] Abe-Dohmae S, Ikeda Y, Matsuo M, et al.Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein[J]. J Biol Chem, 2004, 279(1): 604-611.
[83] Lambert JC, Ibrahim-Verbaas CA, Harold D, et al.Meta-analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease[J]. Nat Genet, 2013, 45(12): 1452-1458.
[84] Karch CM, Jeng AT, Nowotny P, et al.Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains[J]. PLoS One, 2012,7(11):e50976.
[85] Vasquez JB, Fardo DW, Estus S.ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status[J]. Neurosci Lett, 2013, 556: 58-62.
[86] Kim WS, Li H, Ruberu K, et al.Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease[J]. J Neurosci, 2013, 33(10): 4387-4394.
[87] Ehehalt R, Keller P, Haass C, et al.Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts[J]. J Cell Biol, 2003, 160(1): 113-123.
[88] Cheng H, Vetrivel KS, Gong P, et al.Mechanisms of disease: new therapeutic strategies for Alzheimer's disease-targeting APP processing in lipid rafts[J]. Nat Clin Pract Neurol, 2007, 3(7): 374-382.
[89] Yuksel M, Tacal O.Trafficking and proteolytic processing of amyloid precursor protein and secretases in Alzheimer's disease development: An up-to-date review[J]. Eur J Pharmacol, 2019, 856: 172415.
[90] Mukadam AS, Breusegem SY, Seaman MNJ.Analysis of novel endosome-to-Golgi retrieval genes reveals a role for PLD3 in regulating endosomal protein sorting and amyloid precursor protein processing[J]. Cell Mol Life Sci, 2018, 75(14): 2613-2625.
[91] Cheng F, Cappai R, Lidfeldt J, et al.Amyloid precursor protein (APP) /APP-like protein 2(APLP2) expression is required to initiate endosome-nucleus-autophagosome trafficking of glypican-1-derived heparan sulfate[J]. J Biol Chem, 2014, 289(30): 20871-20878.
[92] Kojro E, Gimpl G, Lammich S, et. al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10[J]. Proc Natl Acad Sci U S A, 2001, 98(10): 5815-5820.
[93] Puglielli L, Ellis BC, Saunders AJ, et al.Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis[J]. J Biol Chem, 2003, 278(22): 19777-19783.
[94] Grimm MO, Grimm HS, Pätzold AJ, et al.Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin[J]. Nat Cell Biol, 2005, 7(11): 1118-1123.
[95] He X, Huang Y, Li B, et al.Deregulation of sphingolipid metabolism in Alzheimer's disease[J]. Neurobiol Aging, 2010, 31(3): 398-408.
[96] Leng F, Edison P.Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?[J]. Nat Rev Neurol, 2021, 17(3): 157-172.
[97] Daynes RA, Jones DC.Emerging roles of PPARs in inflammation and immunity[J]. Nat Rev Immunol, 2002, 2(10): 748-759.
[98] Wang WY, Tan MS, Yu JT, et al.Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease[J]. Ann Transl Med, 2015, 3(10): 136.
[99] Zhu L, Liu X, Nemeth DP, et al.Interleukin-1 causes CNS inflammatory cytokine expression via endothelia-microglia bi-cellular signaling[J]. Brain Behav Immun, 2019, 81: 292-304.
[100] Chiurchiu V, Leuti A, Maccarrone M.Bioactive Lipids and Chronic Inflammation: Managing the Fire Within[J]. Front Immunol, 2018, 9: 38.
[101] Maclean FL, Horne MK, Williams RJ, et al.Review: Biomaterial systems to resolve brain inflammation after traumatic injury[J]. APL Bioeng, 2018, 2(2): 021502.
[102] Basil MC, Levy BD.Specialized pro-resolving mediators: endogenous regulators of infection and inflammation[J]. Nat Rev Immunol, 2016, 16(1): 51-67.
[103] Wang X, Zhu M, Hjorth E, et al.Resolution of inflammation is altered in Alzheimer's disease[J]. Alzheimers Dement, 2015, 11(1): 40-50.
[104] Kantarci A, Aytan N, Palaska I, et al.Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease[J]. Exp Neurol, 2018, 300: 111-120.
[105] Dunn HC, Ager RR, Baglietto-Vargas D, et al.Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model[J]. J Alzheimers Dis, 2015, 43(3): 893-903.
[106] Ricciotti E, FitzGerald GA. Prostaglandins and inflammation[J]. Arterioscler Thromb Vasc Biol, 2011, 31(5): 986-1000.
[107] Iyú D, Jüttner M, Glenn JR, et al.PGE1 and PGE2 modify platelet function through different prostanoid receptors[J]. Prostaglandins Other Lipid Mediat, 2011, 94(1-2): 9-16.
[108] Montine TJ, Sidell KR, Crews BC, et al.Elevated CSF prostaglandin E2 levels in patients with probable AD[J]. Neurology, 1999, 53(7): 1495-1498.
[109] Minhas PS, Latif-Hernandez A, McReynolds MR, et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing[J]. Nature, 2021, 590(7844): 122-128.
[110] Shi J, Wang Q, Johansson JU, et al.Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease[J]. Ann Neurol, 2012, 72(5): 788-798.
[111] Liang X, Wang Q, Hand T, et al.Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease[J]. J Neurosci, 2005, 25(44): 10180-10187.
[112] Johansson JU, Woodling NS, Wang Q, et al.Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models[J]. J Clin Invest, 2015, 125(1): 350-364.
[113] Segarra M, Aburto MR, Acker-Palmer A.Blood-Brain Barrier Dynamics to Maintain Brain Homeostasis[J]. Trends Neurosci, 2021, 44(5): 393-405.
[114] Ben-Zvi A, Lacoste B, Kur E, et al.Mfsd2a is critical for the formation and function of the blood-brain barrier[J]. Nature, 2014, 509(7501): 507-511.
[115] Andreone BJ, Chow BW, Tata A, et al. Blood-Brain Barrier Permeability Is Regulated by Lipid Transport-Dependent Suppression of Caveolae-Mediated Transcytosis[J]. Neuron, 2017, 94(3): 581-594. e5.
[116] Pan Y, Choy KHC, Marriott PJ, et al.Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid diets[J]. J Neurochem, 2018, 144(1): 81-92.
[117] Belayev L, Hong SH, Menghani H, et al.Docosanoids Promote Neurogenesis and Angiogenesis, Blood-Brain Barrier Integrity, Penumbra Protection, and Neurobehavioral Recovery After Experimental Ischemic Stroke[J]. Mol Neurobiol, 2018, 55(8): 7090-7106.
[118] Yin F, Sancheti H, Cadenas E.Mitochondrial thiols in the regulation of cell death pathways[J]. Antioxid Redox Signal, 2012, 17(12): 1714-1727.
[119] Apak R, Özyürek M, Güçlü K, et al.Antioxidant Activity/Capacity Measurement.3. Reactive Oxygen and Nitrogen Species (ROS/RNS) Scavenging Assays, Oxidative Stress Biomarkers, and Chromatographic/Chemometric Assays[J]. J Agric Food Chem, 2016, 64(5): 1046-1070.
[120] Hameister R, Kaur C, Dheen ST, et al.Reactive oxygen/nitrogen species (ROS/RNS) and oxidative stress in arthroplasty[J]. J Biomed Mater Res B Appl Biomater, 2020, 108(5): 2073-2087.
[121] Cheignon C, Jones M, Atrián-Blasco E, et al.Identification of key structural features of the elusive Cu-Abeta complex that generates ROS in Alzheimer's disease[J]. Chem Sci, 2017, 8(7): 5107-5118.
[122] Goodman LD, Bellen HJ.Recent insights into the role of glia and oxidative stress in Alzheimer's disease gained from Drosophila[J]. Curr Opin Neurobiol, 2022, 72: 32-38.
[123] Sultana R, Perluigi M, Butterfield DA.Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain[J]. Free Radic Biol Med, 2013, 62: 157-169.
[124] Cheignon C, Tomas M, Bonnefont-Rousselot D, et al.Oxidative stress and the amyloid beta peptide in Alzheimer's disease[J]. Redox Biol, 2018, 14: 450-464.
[125] Markesbery WR, Kryscio RJ, Lovell MA, et al.Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment[J]. Ann Neurol, 2005, 58(5): 730-750.
[126] Prasad VV, Nithipatikom K, Harder DR.Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes[J]. Neurochem Int, 2008, 53(6-8): 220-229.
[127] Dinkins MB, Enasko J, Hernandez C, et al.Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse[J]. J Neurosci, 2016, 36(33): 8653-8667.
[128] Lee JK, Jin HK, Park MH, et al.Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer's disease[J]. J Exp Med, 2014, 211(8): 1551-1570.
[129] Panchal M, Gaudin M, Lazar AN, et al.Ceramides and sphingomyelinases in senile plaques[J]. Neurobiol Dis, 2014, 65: 193-201.
[130] Kao YC, Ho PC, Tu YK, et al.Lipids and Alzheimer's Disease[J]. Int J Mol Sci, 2020, 21(4): 1505.
[131] Kivipelto M, Helkala EL, Laakso MP, et al.Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease[J]. Ann Intern Med, 2002, 137(3): 149-155.
[132] Solomon A, Kåreholt I, Ngandu T, et al.Serum total cholesterol, statins and cognition in non-demented elderly[J]. Neurobiol Aging, 2009, 30(6): 1006-1009.
[133] Corder EH, Saunders AM, Strittmatter WJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families[J]. Science, 1993, 261(5123): 921-923.